CHRM3, Polyclonal Antibody

Muscarinic acetylcholine receptor M3; CHRM3

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

Ig

Rabbit

This CHRM3 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 233-264 amino acids from the Central region of human CHRM3.

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Maintain refrigerated at 2-8 degree C for up to 6 months. For long term storage store at -20 degree C in small aliquots to prevent freeze-thaw cycles.

Small volumes of anti-CHRM3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.

New Antibodies; Primary Antibodies; Neuroscience

Western Blot (WB), ELISA (EIA)

WB:~~1:16000

All lanes : Anti-CHRM3 Antibody (Center) at 1:16000 dilution
Lane 1: KG-1 whole cell lysate
Lane 2: SW620 whole cell lysate
Lysates/proteins at 20 ug per lane.
Secondary
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution.
Predicted band size : 66 kDa
Blocking/Dilution buffer: 5% NFDM/TBST.

66128 Da

cholinergic receptor muscarinic 3

muscarinic acetylcholine receptor M3

Muscarinic acetylcholine receptor M3

ACM3_HUMAN

The muscarinic cholinergic receptors belong to a larger family of G protein-coupled receptors. The functional diversity of these receptors is defined by the binding of acetylcholine and includes cellular responses such as adenylate cyclase inhibition, phosphoinositide degeneration, and potassium channel mediation. Muscarinic receptors influence many effects of acetylcholine in the central and peripheral nervous system. The muscarinic cholinergic receptor 3 controls smooth muscle contraction and its stimulation causes secretion of glandular tissue. [provided by RefSeq, Jul 2008]

mAChR M3: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover. Defects in CHRM3 are the cause of Eagle-Barrett syndrome (EGBRS). EGBRS is a syndrome characterized by thin abdominal musculature with overlying lax skin, cryptorchism, megacystis with disorganized detrusor muscle, and urinary tract abnormalities. Belongs to the G-protein coupled receptor 1 family. Muscarinic acetylcholine receptor subfamily. CHRM3 sub-subfamily.

Protein type: GPCR, family 1; Membrane protein, integral; Membrane protein, multi-pass; Receptor, GPCR

Chromosomal Location of Human Ortholog: 1q43

Cellular Component: asymmetric synapse; basolateral plasma membrane; cell junction; dendrite; integral to plasma membrane; nerve terminal; plasma membrane; postsynaptic membrane; synapse

Molecular Function: acetylcholine binding; drug binding; G-protein coupled acetylcholine receptor activity; phosphoinositide phospholipase C activity; protein binding; receptor activity

Biological Process: acetylcholine receptor signaling, muscarinic pathway; cell proliferation; G-protein coupled receptor protein signaling pathway; muscarinic acetylcholine receptor, adenylate cyclase inhibiting pathway; muscarinic acetylcholine receptor, phospholipase C activating pathway; nervous system development; positive regulation of smooth muscle contraction; protein modification process; regulation of vascular smooth muscle contraction; saliva secretion; signal transduction; smooth muscle contraction; synaptic transmission, cholinergic

Disease: Abdominal Muscles, Absence Of, With Urinary Tract Abnormality And Cryptorchidism

Peralta E.G.,et al.EMBO J. 6:3923-3929 (1987). Bonner T.I.,et al.Neuron 1:403-410 (1988). Kitano T.,et al.Mol. Biol. Evol. 21:936-944 (2004). Puhl H.L. III,et al.Submitted (APR-2002) to the EMBL/GenBank/DDBJ databases. Gregory S.G.,et al.Nature 441:315-321 (2006).

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.